Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence

被引:16
|
作者
Milman, Garry [1 ]
Bergamaschi, Mateus M. [1 ]
Lee, Dayong [1 ]
Mendu, Damodara R. [1 ]
Barnes, Allan J. [1 ]
Vandrey, Ryan [2 ]
Huestis, Marilyn A. [1 ]
机构
[1] NIDA, Chem & Drug Metab Sect, Intramural Res Program, Biomed Res Ctr,NIH, Baltimore, MD 21224 USA
[2] Johns Hopkins Bayview Med Ctr, Behav Pharmacol Res Unit, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
dronabinol; plasma; cannabinoids; smoking; oral administration; ORAL THC; DELTA-9-TETRAHYDROCANNABINOL CONCENTRATIONS; TOBACCO WITHDRAWAL; MARIJUANA; SMOKING; BLOOD; DELTA(9)-TETRAHYDROCANNABINOL; ABSORPTION; THCCOOH; IMPACT;
D O I
10.1097/FTD.0b013e3182a5c446
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background:Recently, high-dose oral synthetic delta-9-tetrahydrocannabinol (THC) was shown to alleviate cannabis withdrawal symptoms. The present data describe cannabinoid pharmacokinetics in chronic, daily cannabis smokers who received high-dose oral THC pharmacotherapy and later a smoked cannabis challenge.Methods:Eleven daily cannabis smokers received 0, 30, 60, or 120 mg/d THC for four 5-day medication sessions, each separated by 9 days of ad libitum cannabis smoking. On the fifth day, participants were challenged with smoking one 5.9% THC cigarette. Plasma collected on the first and fifth days was quantified by two-dimensional gas chromatography mass spectrometer for THC, 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Linear ranges (ng/mL) were 0.5-100 for THC, 1-50 for 11-OH-THC, and 0.5-200 for THCCOOH.Results:During placebo dosing, THC, 11-OH-THC, and THCCOOH concentrations consistently decreased, whereas all cannabinoids increased dose dependently during active dronabinol administration. THC increase over time was not significant after any dose, 11-OH-THC increased significantly during the 60- and 120-mg/d doses, and THCCOOH increased significantly only during the 120-mg/d dose. THC, 11-OH-THC, and THCCOOH concentrations peaked within 0.25 hours after cannabis smoking, except after 120 mg/d THC when THCCOOH peaked 0.5 hours before smoking.Conclusions:The significant withdrawal effects noted during placebo dronabinol administration were supported by significant plasma THC and 11-OH-THC concentration decreases. During active dronabinol dosing, significant dose-dependent increases in THC and 11-OH-THC concentrations support withdrawal symptom suppression. THC concentrations after cannabis smoking were only distinguishable from oral THC doses for 1 hour, too short a period to feasibly identify cannabis relapse. THCCOOH/THC ratios were higher 14 hours after overnight oral dronabinol abstinence but cannot distinguish oral THC dosing from the smoked cannabis intake.
引用
收藏
页码:218 / 224
页数:7
相关论文
共 50 条
  • [41] Time course of cannabinoid accumulation and chemotype development during the growth of Cannabis sativa L
    Pacifico, D.
    Miselli, F.
    Carboni, A.
    Moschella, A.
    Mandolino, G.
    EUPHYTICA, 2008, 160 (02) : 231 - 240
  • [42] Delineating genetic regulation of cannabinoid biosynthesis during female flower development in Cannabis sativa
    Apicella, Peter, V
    Sands, Lauren B.
    Ma, Yi
    Berkowitz, Gerald A.
    PLANT DIRECT, 2022, 6 (06)
  • [43] Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing
    Raber, Jeffrey C.
    Elzinga, Sytze
    Kaplan, Charles
    JOURNAL OF TOXICOLOGICAL SCIENCES, 2015, 40 (06): : 797 - 803
  • [44] Identification of Recent Cannabis Use: Whole-Blood and Plasma Free and Glucuronidated Cannabinoid Pharmacokinetics following Controlled Smoked Cannabis Administration
    Schwope, David M.
    Karschner, Erin L.
    Gorelick, David A.
    Huestis, Marilyn A.
    CLINICAL CHEMISTRY, 2011, 57 (10) : 1406 - 1414
  • [45] Plasma concentrations of nitric oxide in the patients with alcohol dependence
    Joe, K. H.
    Kim, D. J.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2006, 30 (06) : 38A - 38A
  • [46] Applying machine learning to international drug monitoring: classifying cannabis resin collected in Europe using cannabinoid concentrations
    Freeman, Tom P.
    Beeching, Edward
    Craft, Sam
    Di Forti, Marta
    Frison, Giampietro
    Lindholst, Christian
    Oomen, Pieter E.
    Potter, David
    Rigter, Sander
    Thomsen, Kristine Romer
    Zamengo, Luca
    Cunningham, Andrew
    Groshkova, Teodora
    Sedefov, Roumen
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2025, 275 (02) : 421 - 429
  • [47] Methadone disposition in oral fluid during pharmacotherapy for opioid-dependence
    Gray, Teresa R.
    Dams, Riet
    Choo, Robin E.
    Jones, Hendree E.
    Huestis, Marilyn A.
    FORENSIC SCIENCE INTERNATIONAL, 2011, 206 (1-3) : 98 - 102
  • [48] DECREASED BRAIN CANNABINOID RECEPTOR (CB1R) AVAILABILITY IN CANNABIS DEPENDENCE RAPIDLY NORMALIZES WITH ABSTINENCE
    D'Souza, Deepak Cyril
    Cortes, Jose
    Ranganathan, Mohini
    Thurnauer, Halle
    Planeta, Beata
    Radhakrishnan, Rajiv
    Huang, Yiyung
    Carson, Richard
    Skosnik, Patrick
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S187 - S187
  • [49] Plasma Cannabinoid Pharmacokinetics following Controlled Oral Δ9-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration
    Karschner, Erin L.
    Darwin, W. David
    Goodwin, Robert S.
    Wright, Stephen
    Huestis, Marilyn A.
    CLINICAL CHEMISTRY, 2011, 57 (01) : 66 - 75
  • [50] PLASMA HISTAMINE CONCENTRATIONS DURING ENDOTOXEMIA
    BRACKETT, DJ
    HAMBURGER, SA
    LERNER, MR
    LANDER, TJ
    SCHAEFER, CF
    HENRY, DP
    WILSON, MF
    CIRCULATORY SHOCK, 1987, 21 (04) : 305 - 306